Monte Carlo simulations: Maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients

Journal of Antimicrobial Chemotherapy

Volumn 66, Issue 2, 2011, Pages 227-231

  Roberts, Jason A ^a,b   Kirkpatrick, Carl M J ^a   Lipman, Jeffrey ^a,b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

Dosing; Minimum inhibitory concentration; Pharmacodynamics; Population pharmacokinetics; Susceptibility

Indexed keywords

ANTIBIOTIC AGENT; CEFEPIME; CEFTOBIPROLE; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL PRACTICE; CRITICALLY ILL PATIENT; DRUG EFFICACY; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD;

ANTI-BACTERIAL AGENTS; BIOMARKERS, PHARMACOLOGICAL; CRITICAL CARE; CRITICAL ILLNESS; HUMANS; MICROBIAL SENSITIVITY TESTS; MONTE CARLO METHOD; TREATMENT OUTCOME;

EID: 78651413706     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq449     Document Type: Article

References (25)

1. Finfer S, Bellomo R, Lipman J, et al. Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med 2004; 30: 589-96.
2. Bellomo R, Cass A, Cole L, et al. Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med 2009; 361: 1627-38.
3. Kollef MH, Sherman G, Ward S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115: 462-74.
4. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-96.
5. Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-81.
6. Rayner CR, Forrest A, Meagher AK, et al. Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-23.
7. Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve:minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis 2004; 189: 1590-7.
8. McKinnon PS, Paladino JA, Schentag JJ. Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 2008; 31: 345-51.
9. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-10; quiz 11-2.
10. Drusano GL. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'. Nat Rev Microbiol 2004; 2: 289-300.
11. Roberts JA, Kruger P, Paterson DL, et al. Antibiotic resistance-what's dosing got to do with it? Crit Care Med 2008; 36: 2433-40.
12. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37: 840-51.
13. Bonate PL. A brief introduction to Monte Carlo simulation. Clin Pharmacokinet 2001; 40: 15-22.
14. Udy AA, Roberts JA, Boots RJ, et al. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet 2010; 49: 1-16.
15. Tam VH, Kabbara S, Yeh RF, et al. Impact of sample size on the performance of multiple-model pharmacokinetic simulations. Antimicrob Agents Chemother 2006; 50: 3950-2.
16. Roberts JA, Kirkpatrick CMJ, Roberts MS, et al. Meropenem dosing in critically ill patients with sepsis and without renal dysfunction: intermittent bolus versus continuous administration? Monte Carlo dosing simulations and subcutaneous tissue distribution. J Antimicrob Chemother 2009; 64: 142-50.
17. Samtani MN, Flamm R, Kaniga K, et al. Pharmacokineticpharmacodynamic-model-guided doripenem dosing in critically ill patients. Antimicrob Agents Chemother 2010; 54: 2360-4.
18. Zelenitsky SA, Ariano RE, Zhanel GG. Pharmacodynamics of empirical antibiotic monotherapies for an intensive care unit (ICU) population based on Canadian surveillance data. J Antimicrob Chemother 2011; 66: 343-349.
19. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
20. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
21. Martin JH, Fay MF, Udy AA, et al. Pitfalls of using estimations of glomerular filtration rate in an intensive care population. Intern Med J 2010; doi:10.1111/j.1445-5994.2010.02160.x.
22. Wells M, Lipman J. Measurements of glomerular filtration in the intensive care unit are only a rough guide to renal function. S Afr J Surg 1997; 35: 20-3.
23. Ulldemolins M, Roberts JA, Rello J, et al. The effects of hypoalbuminaemia on optimising antibiotic dosing in critically ill patients. Clin Pharmacokinet 2010; in press.
24. Ulldemolins M, Roberts JA, Wallis SC, et al. Flucloxacillin dosing in critically ill patients with hypoalbuminaemia: special emphasis on unbound pharmacokinetics. J Antimicrob Chemother 2010; 65: 1771-8.
25. BurkhardtO, KumarV, Katterwe D, et al. Ertapenemin critically ill patients with early-onset ventilator-associated pneumonia: pharmacokinetics with special consideration of free-drug concentration. J Antimicrob Chemother 2007; 59: 277-84